Adiumentum Capital Fund I LP Files 13D on Atara Biotherapeutics
Ticker: ATRA · Form: SC 13D · Filed: May 22, 2024 · CIK: 1604464
| Field | Detail |
|---|---|
| Company | Atara Biotherapeutics, INC. (ATRA) |
| Form Type | SC 13D |
| Filed Date | May 22, 2024 |
| Risk Level | medium |
| Pages | 7 |
| Reading Time | 9 min |
| Key Dollar Amounts | $0.0001, $5,643,549.82 |
| Sentiment | neutral |
Sentiment: neutral
Topics: ownership-change, activist-filing, biotech
Related Tickers: ATRA
TL;DR
**13D FILED ON ATARA BIO!** Adiumentum Capital Fund I LP now has a stake.
AI Summary
On May 22, 2024, Adiumentum Capital Fund I LP, along with Gregory A. Ciongoli, filed a Schedule 13D regarding Atara Biotherapeutics, Inc. This filing indicates a change in beneficial ownership of the company's common stock. The filing was made under the Securities Exchange Act of 1934.
Why It Matters
This filing signals a significant investor's increased attention or potential strategic interest in Atara Biotherapeutics, which could influence the company's stock performance and corporate actions.
Risk Assessment
Risk Level: medium — Schedule 13D filings often precede significant corporate events or activist investor campaigns, introducing potential volatility.
Key Players & Entities
- Adiumentum Capital Fund I LP (company) — Filing entity
- Gregory A. Ciongoli (person) — Filing entity member
- Atara Biotherapeutics, Inc. (company) — Subject company
- Cadwalader, Wickersham & Taft LLP (company) — Legal counsel
- Richard M. Brand (person) — Legal counsel
- Erica L. Hogan (person) — Legal counsel
FAQ
What is the primary purpose of this Schedule 13D filing?
The filing is to report a change in beneficial ownership of Atara Biotherapeutics, Inc. common stock by Adiumentum Capital Fund I LP and Gregory A. Ciongoli.
Who are the main parties involved in this filing?
The filing involves Adiumentum Capital Fund I LP, Gregory A. Ciongoli, and the subject company Atara Biotherapeutics, Inc.
When was this filing made?
The filing was made on May 22, 2024.
What is the CUSIP number for Atara Biotherapeutics, Inc. common stock?
The CUSIP number for Atara Biotherapeutics, Inc. common stock is 046513107.
What is the business address of Atara Biotherapeutics, Inc. as listed in the filing?
The business address is 2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA 91320.
Filing Stats: 2,204 words · 9 min read · ~7 pages · Grade level 10.2 · Accepted 2024-05-22 18:18:00
Key Financial Figures
- $0.0001 — me of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti
- $5,643,549.82 — ly owned by Adiumentum is approximately $5,643,549.82. The source of funding for such transac
Filing Documents
- tm2415124d1_sc13d.htm (SC 13D) — 57KB
- tm2415124d1_ex99-1.htm (EX-99.1) — 6KB
- tm2415124d1_ex99-2.htm (EX-99.2) — 79KB
- 0001104659-24-064358.txt ( ) — 144KB
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct. Date: May 22, 2024 ADIUMENTUM CAPITAL FUND I LP By: Adiumentum Capital Fund I GP LLC, its general partner By: /s/ Gregory A. Ciongoli Name: Gregory A. Ciongoli Title: Managing Member Date: May 22, 2024 ADIUMENTUM CAPITAL FUND I GP LLC By: /s/ Gregory A. Ciongoli Name: Gregory A. Ciongoli Title: Managing Member Date: May 22, 2024 GREGORY A. CIONGOLI By: /s/ Gregory A. Ciongoli Gregory A. Ciongoli -8-